CIBC World Market
RXRX icon

CIBC World Market’s Recursion Pharmaceuticals RXRX Stock Holding History

CIBC World Market’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.4K Sell
24,360
-13,119
-35% -$43.7K ﹤0.01% 1515
2026
Q1 		$115K Sell
37,479
-469
-1% -$1.81K ﹤0.01% 1426
2025
Q4 		$155K Sell
37,948
-18,583
-33% -$92K ﹤0.01% 1392
2025
Q3 		$276K Buy
56,531
+15,501
+38% +$81.4K ﹤0.01% 1264
2025
Q2 		$208K Buy
41,030
+22,045
+116% +$108K ﹤0.01% 1275
2025
Q1 		$100K Sell
18,985
-1,932
-9% -$14.1K ﹤0.01% 1311
2024
Q4 		$141K Buy
20,917
+2,782
+15% +$18.7K ﹤0.01% 1304
2024
Q3 		$120K Sell
18,135
-1,678
-8% -$12K ﹤0.01% 1254
2024
Q2 		$149K Sell
19,813
-254
-1% -$2.21K ﹤0.01% 1210
2024
Q1 		$200K Sell
20,067
-1,048
-5% -$11.7K ﹤0.01% 1227
2023
Q4 		$208K Buy
21,115
+4
+0% +$29 ﹤0.01% 1166
2023
Q3 		$161K Buy
+21,111
New +$211K ﹤0.01% 1165

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CIBC World Market's RXRX Position: Q2 2026 in Review

CIBC World Market reduced its Recursion Pharmaceuticals (RXRX) stake by 35% in Q2 2026, selling an estimated $43.7K and leaving 24,360 shares worth $89.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

CIBC World Market first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $276K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • CIBC World Market held 24,360 shares of Recursion Pharmaceuticals worth $89.4K as of Q2 2026.
  • CIBC World Market sold 13,119 Recursion Pharmaceuticals shares in Q2 2026, an estimated $43.7K.
  • Recursion Pharmaceuticals made up ﹤0.01% of CIBC World Market's portfolio in Q2 2026, its #1515 holding.
  • CIBC World Market first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • CIBC World Market's Recursion Pharmaceuticals position peaked at $276K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on CIBC World Market's 13F filing for Q2 2026, filed 13 Aug 2026.